Document is current
Any future updates will be listed below
-
Authors
Müller, Bettina
Ruby, Lisa
Jordan, Suzana
Rominger, Marga B.
Mazza, Edoardo
Distler, Oliver http://orcid.org/0000-0002-0546-8310
-
Funding
Funding for this research was provided by:
Helmut Horten Stiftung
- License Information
-
More Information
Article History
Received: 5 March 2020
Accepted: 12 May 2020
First Online: 3 June 2020
Ethics approval and consent to participate
: This manuscript describes the outcome of an interventional medical device study, which was registered at ExternalRef removed (NCT03644225). Ethical approval was obtained from the local ethics committee Cantonal Ethics Committee Zurich, with the reference number KEK-ZH-Nr. 2017-01154, and from the Swiss National Agency for Therapeutic Products with the reference number Swissmedic 2017-MD-0045.
: Not applicable.
: Prof. Dr. O. Distler had consultancy relationship and/or has received research funding from Abbvie, Actelion, Acceleron Pharma, Amgen, AnaMar, Baecon Discovery, Blade Therapeutics, Bayer, Boehringer Ingelheim, Catenion, Competitive Drug Development International Ltd., CSL Behring, ChemomAb, Curzion Pharmaceuticals, Ergonex, Galapagos NV, Glenmark Pharmaceuticals, GSK, Inventiva, Italfarmaco, iQone, iQvia, Lilly, medac, Medscape, Mitsubishi Tanabe Pharma, MSD, Novartis, Pfizer, Roche, Sanofi, Target Bio Science, and UCB in the area of potential treatments of scleroderma and its complications. In addition, Prof. Distler has a patent mir-29 for the treatment of systemic sclerosis issued (US8247389, EP2331143). Author Prof. Dr. Edoardo Mazza is coinventor of the related technology, described in the patent: Aspiration Device and Method for Determining Viscoelastic Properties of Biological Tissues and Synthetic Materials, EP16197195.7. The other authors declare that they have no competing interests.
